One preliminary experience in adults suggested that the use of the IL-6 receptor antibody tocilizumab is beneficial in patients with hematological malignancy who suffer from elevated IL-6 levels caused by severe sepsis [13]. This evidence concerns the gene IL6 and hematologic disorder.